The Health and Social Care Committee will hold a public hearing on the availability and pricing of Orkambi and other cystic fibrosis drugs manufactured by Vertex Pharmaceuticals on the NHS on Thursday 7 March.
Focus of the session
The Committee will hear from representatives of Vertex, NHS England and the National Institute for Health and Care Excellence (NICE).
The session will explore the current impasse between Vertex, NHS England and NICE concerning negotiations on the availability of these drugs to NHS patients in England.
Further details of the session will be confirmed.
Call for submissions
Anybody who wishes to bring information to the Committee’s attention ahead of the session should do so via this submissions form.
Submissions should be made by Monday 25 February. Brief submissions (fewer than 2000 words) are preferred.